Scan to Download
One power score. Smarter investment decisions
Zenas Biopharma Inc
ZBIO19.460USD
+0.395+2.07%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
0.000USD0.000Pre-market 09/19, 09:30 (ET)
819.05MMarket Cap
LossP/E TTM
Zenas Biopharma Inc
19.460
+0.395+2.07%
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
Total revenue
--0.00
--10.00M
--5.00M
-100.00%0.00
----
----
--0.00
--50.00M
----
----
--0.00
Revenue
--0.00
--10.00M
--5.00M
-100.00%0.00
----
----
--0.00
--50.00M
----
----
--0.00
Operating expenses
38.94%55.16M
71.62%47.33M
144.65%60.62M
185.07%40.98M
110.01%39.70M
44.49%27.58M
30.49%24.78M
--14.38M
--18.91M
--19.09M
--18.99M
R&D expenses
27.27%43.03M
54.18%34.91M
140.75%49.16M
258.49%33.53M
126.66%33.81M
47.55%22.64M
29.51%20.42M
--9.35M
--14.91M
--15.35M
--15.77M
Depreciation, depletion, and amortization
-65.71%12.00K
-30.30%23.00K
10.00%33.00K
38.46%36.00K
20.69%35.00K
17.86%33.00K
20.00%30.00K
--26.00K
--29.00K
--28.00K
--25.00K
Operating profit
-38.94%-55.16M
-35.36%-37.33M
-124.48%-55.62M
-215.05%-40.98M
-110.01%-39.70M
-44.49%-27.58M
-30.49%-24.78M
--35.62M
---18.91M
---19.09M
---18.99M
Net non-operating interest income (expenses)
Special income (expenses)
100.00%0.00
100.00%0.00
100.00%0.00
--0.00
98.48%-152.00K
---694.00K
---300.00K
--0.00
---10.00M
--0.00
--0.00
Other non-operating income (expenses)
57.70%2.96M
652.54%3.55M
334.80%3.45M
14962.50%2.38M
1421.83%1.88M
4390.91%472.00K
15960.00%793.00K
---16.00K
---142.00K
---11.00K
---5.00K
Income before tax
-37.46%-52.20M
-21.50%-33.78M
-114.84%-52.17M
-208.42%-38.61M
-30.74%-37.98M
-45.57%-27.80M
-27.86%-24.29M
--35.61M
---29.05M
---19.10M
---18.99M
Income tax
--20.00K
---205.00K
42.52%429.00K
----
----
----
--301.00K
----
----
----
--0.00
Income after tax
-37.51%-52.22M
-20.77%-33.57M
-113.95%-52.60M
-208.42%-38.61M
-30.74%-37.98M
-45.57%-27.80M
-29.45%-24.59M
--35.61M
---29.05M
---19.10M
---18.99M
Net income from continuous operations
-37.51%-52.22M
-20.77%-33.57M
-113.95%-52.60M
-208.42%-38.61M
-30.74%-37.98M
-45.57%-27.80M
-29.45%-24.59M
--35.61M
---29.05M
---19.10M
---18.99M
Net income attributable to controlling interests
-37.51%-52.22M
-20.77%-33.57M
-113.95%-52.60M
-208.42%-38.61M
-30.74%-37.98M
-45.57%-27.80M
-29.45%-24.59M
--35.61M
---29.05M
---19.10M
---18.99M
Net income attributable to common shareholders
-37.51%-52.22M
-20.77%-33.57M
-113.95%-52.60M
-208.42%-38.61M
-30.74%-37.98M
-45.57%-27.80M
-29.45%-24.59M
--35.61M
---29.05M
---19.10M
---18.99M
Basic earnings per share
-30.70%-1.25
-14.96%-0.80
-1420.62%-9.40
-203.26%-0.92
-30.74%-0.95
-45.57%-0.70
-29.45%-0.62
--0.89
---0.73
---0.48
---0.48
Diluted earnings per share
-30.70%-1.25
-14.96%-0.80
-1420.62%-9.40
-203.26%-0.92
-30.74%-0.95
-45.57%-0.70
-29.45%-0.62
--0.89
---0.73
---0.48
---0.48
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Audit opinions
--
--
--
--
--
--
--
--
--
--
--
